The report from biotechnology consultants Critical I compares the state of the European biotechnology industry with that of the U.S., and concludes Europe has much to do to catch up with the U.S., citing a lack of access to financing as the largest obstacle European companies face. The report says the financing problem is most acute later in the business cycle, leading many companies to fold after three to five years.

Full Story:

Related Summaries